NCT06791421 AI-Driven Genotype Prediction Using EHR and Multimodal Data
| NCT ID | NCT06791421 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Eye Hospital of Wenzhou Medical University |
| Condition | Genotype |
| Study Type | OBSERVATIONAL |
| Enrollment | 100,000 participants |
| Start Date | 2023-07-01 |
| Primary Completion | 2025-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100,000 participants in total. It began in 2023-07-01 with a primary completion date of 2025-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical study is to explore the potential of using electronic health records (EHR) and multimodal data (such as imaging, lab results, and clinical history) to predict a patient's genotype. The study will evaluate whether predictive models based on this non-genetic data can accurately infer genetic information, which traditionally requires direct genetic testing.
Eligibility Criteria
Inclusion Criteria: 1. Participants must have comprehensive electronic health records (EHR), including medical history, lab results, and relevant imaging data (e.g., X-rays, MRIs, CT scans). 2. Participants must have existing genetic testing data available for comparison, if applicable. 3. Participants must be willing to provide consent for the use of their health data in the study. 4. Participants must have no active intervention related to genetic testing or prediction during the study period. 5. Participants should have complete and verifiable health data to allow for accurate prediction by the AI model. Exclusion Criteria: 1. Participants without available EHR, lab results, or imaging data. 2. Participants with ambiguous, inaccurate, or unverifiable genetic testing results that cannot be used for comparison. 3. Patients with significant discrepancies or missing data that would prevent the AI model from making accurate predictions.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06791421 clinical trial?
This trial is open to participants of all sexes, studying Genotype. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06791421 currently recruiting?
Yes, NCT06791421 is actively recruiting participants. Contact the research team at liufei_2359@163.com for enrollment information.
Where is the NCT06791421 trial being conducted?
This trial is being conducted at Guangzhou, China, Guangzhou, China, Wenzhou, China, Wenzhou, China.
Who is sponsoring the NCT06791421 clinical trial?
NCT06791421 is sponsored by The Eye Hospital of Wenzhou Medical University. The trial plans to enroll 100,000 participants.